For months, he’s been dangling the carrot of rescheduling cannabis from Schedule I to III, teasing it like the Epstein files or his “no new wars” pledge—empty calories for the faithful. A GOP congressional leader even called it “cautiously optimistic,” framing it as an opioid alternative to keep the base nodding along. But peel back the foil, and it’s clear: this is Pharma’s wet dream.
This column originally appeared in Cultivated, a cannabis industry newsletter. Subscribe here. You know the…
The DEA has opened a new registration process for state-licensed medical cannabis manufacturers, distributors and…
This November gathering will bring psychedelic education into conversation with music, visual art, comedy, philosophy,…
Ten p.m. on a Glendale balcony, two floors above the theater that just screened the…
We analyzed seven different 2026 rankings to find the true top 10 cannabis strains in…
A land-rooted look at the growers reshaping cannabis through living soil, ecological intelligence and regenerative…